Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males

Blood

Volumn 93, Issue 7, 1999, Pages 2186-2190

  Inbal, Aida ^a   Freimark, Dov ^b   Modan, Baruch ^b   Chetrit, Angela ^b   Matetzky, Shlomi ^b   Rosenberg, Nurit ^b   Dardik, Rima ^b   Baron, Zvia ^b   Seligsohn, Uri ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROGENESIS; CORONARY RISK; DIABETES MELLITUS; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING;

EID: 0033121115     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.7.2186     Document Type: Article

References (45)

1. Fuster V: Mechanisms leading to myocardial infarction insights from studies of vascular biology. Circulation 90:2126, 1994
2. Farmer JA, Gotto AM Jr: Dyslipidemia and other risk factors for coronary artery disease, in Braunwald E (ed): Heart Disease. Philadelphia, PA, Saunders, 1997, p 1126
3. Wilson PWF, Shaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16:1250, 1996
4. Yarnell JWG, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC: Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease: The Caerphilly and Speedwell collaborative heart disease studies. Circulation 83:836, 1991
5. Thaulow E., Erikssen J, Sandvik L, Stormorken H, Cohen PF: Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84:613, 1991
6. Wiman B, Hamstein A: Correlations between fibrinolytic function and acute myocardial infarction. Am J Cardiol 66:54G, 1990
7. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson ID, Thomson SG: Haemostatic function in ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 2:533, 1986
8. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635, 1995
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolale reductase. Nat Genet 10:111, 1995
10. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocystein concentrations. Circulation 93:7, 1996
11. Van Bockxmeer FM, Mamotte CDS, Vasikaran SD, Taylor RR: Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 95:21, 1997
12. 677T mutation. Arterioscler Thromb Vasc Biol 16:878, 1996
13. Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ: Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. Q J Med 89:437, 1996
14. Schmitz C, Lindpaintner K, Verhoef P, Gazaino JM, Buring J: Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case-control study. Circulation 94:1812, 1996
15. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt D, Genest J, Rozen R: Correlation of a common mutation in the methylenetetrahydrofolate reductase (MTHFR) gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 17:569, 1997
16. Ma J, Stampfer MJ, Hennekens CH, Forst P, Selhub J, Horsford J, Malinow MR, Willett W, Roze R: Methylenetetrahydrofolate reductase polymorphism and risk of myocardial infarction in the U.S. physicians. Circulation 4:2410, 1996
17. Schwartz SM, Siscovick DS, Malinow R, Rosendaal FR, Beverly K, Hess DL, Psaty BM, Longstreth WT: Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 96:412, 1997
18. Kluijtmans L, van den Heuvel L, Boers G, Frosst P, Stevens E van Oost B, den Heijer M, Trijbels FJ, Rozen R, Blom HJ: Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the 5,10-methylenetetrahydrofolate reductase gene is a genetic factor for cardiovascular disease. Am J Hum Genet 58:35, 1996
19. De Franchis R, Mancini FP, D'Angelo A, Sebastio G, Fermo I, De Stefano V, Margaglione M, Mazzola G, Di Minno G, Andria G: Elevated total plasma homocystein (tHcy) and 677CT mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet 59:262, 1996
20. Morita H, Taguchi JI, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y: Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95:2032, 1997
21. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Driven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
22. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B: Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343:1362, 1994
23. Zoller B, Dahlback B: Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343:1536, 1994
24. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503, 1993
25. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995
26. 506 - Gln factor V mutation (factor V Leiden) in patients with cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73:558, 1995
27. 506 → Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 75:701, 1996
28. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I: Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 345:526, 1995
29. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlback B: Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 239:221, 1996
30. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Raghunathan TE Jr. Koepsell TD, Reitsma PH: Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89:2817, 1997
31. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL: A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 90:1747, 1997
32. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698, 1996
33. Hillarp A, Zoller B, Svensson PJ, Dahlback B: The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 78:990, 1997
34. Ferraresi P, Marchetti G, Legnani C, Cavallari E, Castoldi E, Mascoli F, Ardissino D, Palareti G, Bernardi F: Heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. Arterioscler Thromb Vasc Biol 17:2418, 1997
35. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF: Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 78:1430, 1997
36. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A, O'Leary DH, Psaty B, Rautaharju P, Trac RP, Weiler PG: The Cardiovascular Health Study: Design and rationale. Ann Epidemiol 1:263, 1991
37. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure of extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988
38. Brenner B, Zivelin A, Lanir N, Greengard JS, Griffin JH, Seligsohn U: Venous thromboembolism associated with double heterozygosity for R506Q mutation of factor V and for T298M mutation of protein C in a large family of a previously described homozygous protein C-deficient newborn with massive thrombosis. Blood 8:877, 1996
39. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Seligsohn U: Improved method for the gof apolipoprotein E polymorphisms by PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 43:1657, 1997
40. 506 to Gln factor V mutation and activated protein C resistance. Lancet 345:321, 1995
41. Van Bockxmeer FM, Baker RI, Taylor RR: Premature ischaemic heart disease and the gene for coagulation factor V. Nat Med 1:185, 1995
42. Doggen CJM, Cats VM, Bertina RM, Rosendaal FR: Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 97:1037, 1998
43. Zimmerman FH, Cameron A, Fisher LD, Ng G: Myocardial infarction in young adults: Angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J Am Coll Cardiol 26:654, 1995
44. Girelli D, Friso S, Trabetti E, Olivieri O, Russo C, Pessotto R, Faccini G, Pignatti PF, Mazzucco A, Corrocher R: Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: Evidence for an important genetic-environmental interaction. Blood 91:4158, 1998
45. Dunn ST, Roberts CR, Schechter E, Moore WE, Lee ET, Eichner JE: Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. Thromb Res 91:91, 1998